E-LIB Suche - Ergebnisse für: Elbasha, Elamin

1

Structured Literature Review to Identify Human Papillomavir..:

Diakite, Ibrahim ; Martins, Bruno ; Owusu-Edusei, Kwame...
Infectious Diseases and Therapy. 13 (2024) 5 - p. 965-990 , 2024

Link: https://doi.org/10.1007/..

2

Cost-Effectiveness Analysis of Routine Use of 15-Valent Pne..:

Huang, Min ; Hu, Tianyan ; Weaver, Jessica..
Vaccines. 11 (2023) 1 - p. 135 , 2023

Link: https://doi.org/10.3390/..

3

Modeling the health and economic implications of adopting a..:

Daniels, Vincent ; Saxena, Kunal ; Patterson-Lomba, Oscar...
Vaccine. 40 (2022) 14 - p. 2173-2183 , 2022

Link: https://doi.org/10.1016/..

4

578. Cost-effectiveness of Infant Vaccination with PCV15 Co..:

Huang, Min ; Hu, Tianyan ; Weaver, Jessica..
Open Forum Infectious Diseases. 9 (2022) Supplement_2 - p. , 2022

Link: https://doi.org/10.1093/..

5

Modeling the Impact of Exogenous Boosting and Universal Var..:

Sharomi, Oluwaseun ; Xausa, Ilaria ; Nachbar, Robert...
Vaccines. 10 (2022) 9 - p. 1416 , 2022

Link: https://doi.org/10.3390/..

6

Public health impact and cost-effectiveness of a nine-valen..:

Majed, Laureen ; Bresse, Xavier ; El Mouaddin, Nadia...
Vaccine. 39 (2021) 2 - p. 438-446 , 2021

Link: https://doi.org/10.1016/..

7

Public health impact and cost-effectiveness of catch-up 9-v..:

Daniels, Vincent ; Prabhu, Vimalanand S. ; Palmer, Cody...
Human Vaccines & Immunotherapeutics. 17 (2021) 7 - p. 1943-1951 , 2021

Link: https://doi.org/10.1080/..

8

Cost-effectiveness of Bezlotoxumab Compared With Placebo fo..:

Prabhu, Vimalanand S ; Dubberke, Erik R ; Dorr, Mary Beth...
Clinical Infectious Diseases. 66 (2017) 3 - p. 355-362 , 2017

Link: https://doi.org/10.1093/..

9

Chronic hepatitis C virus (HCV) disease burden and cost in ..:

Razavi, Homie ; ElKhoury, Antoine C. ; Elbasha, Elamin...
Hepatology. 57 (2013) 6 - p. 2164-2170 , 2013

Link: https://doi.org/10.1002/..

10

Human papillomavirus vaccine introduction in low-income and..:

Jit, Mark ; Demarteau, Nadia ; Elbasha, Elamin...
BMC Medicine. 9 (2011) 1 - p. , 2011

Link: https://doi.org/10.1186/..

11

Costs and Benefits of a Subtype-Specific Surveillance Syste..:

Elbasha, Elamin
Emerging Infectious Diseases. 6 (2000) 3 - p. 293-297 , 2000

Link: https://doi.org/10.3201/..

12

Comparison of a static cohort model and dynamic transmissio..:

Lang, John C. ; Kura, Klodeta ; Garba, Salisu M...
Vaccine. 42 (2024) 8 - p. 1918-1927 , 2024

Link: https://doi.org/10.1016/..

13

Cost‑Effectiveness Risk‑Aversion Curves: Comparison of Risk..:

Elbasha, Elamin H.
PharmacoEconomics. 40 (2022) 5 - p. 497-507 , 2022

Link: https://doi.org/10.1007/..

14

Authors' Reply to Comment on "Risk-Adjusted Performance Mea..:

Elbasha, Elamin H.
PharmacoEconomics. 40 (2022) 7 - p. 741-742 , 2022

Link: https://doi.org/10.1007/..

15

Mathematical assessment of the impact of cohort vaccination..:

Malik, Tufail M. ; Mohammed-Awel, Jemal ; Gumel, Abba B..
Journal of Biological Dynamics. 15 (2021) sup1 - p. S214-S247 , 2021

Link: https://doi.org/10.1080/..